ACAD vs. CTLT, SRPT, QGEN, PCVX, ASND, ROIV, RVMD, LNTH, BPMC, and BBIO
Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.
ACADIA Pharmaceuticals vs.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and Catalent (NYSE:CTLT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment.
ACADIA Pharmaceuticals has a net margin of 13.83% compared to Catalent's net margin of -9.28%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Catalent's return on equity.
ACADIA Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Catalent shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ACADIA Pharmaceuticals received 253 more outperform votes than Catalent when rated by MarketBeat users. Likewise, 73.14% of users gave ACADIA Pharmaceuticals an outperform vote while only 57.50% of users gave Catalent an outperform vote.
ACADIA Pharmaceuticals presently has a consensus target price of $25.25, suggesting a potential upside of 41.14%. Catalent has a consensus target price of $63.40, suggesting a potential downside of 0.13%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Catalent.
ACADIA Pharmaceuticals has higher earnings, but lower revenue than Catalent. Catalent is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, ACADIA Pharmaceuticals had 6 more articles in the media than Catalent. MarketBeat recorded 7 mentions for ACADIA Pharmaceuticals and 1 mentions for Catalent. ACADIA Pharmaceuticals' average media sentiment score of 0.66 beat Catalent's score of 0.42 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.
Summary
ACADIA Pharmaceuticals beats Catalent on 16 of the 18 factors compared between the two stocks.
Get ACADIA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACADIA Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ACAD) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ACAD Stock Alerts